Emmaus Life Sciences announced today that its application for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority (SFDA).
Read MoreEmmaus Life Sciences, Inc. announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).
Read MoreEmmaus announced today that its Audit Committee will meet the week of April 19 to review and approve the filing of the company’s 2020 Annual Report on Form 10-K and related earnings release.
Read MoreEmmaus Life Sciences, Inc., announced today that it has entered into an agreement with Kainos Medicine, Inc. (“Kainos”) to lead the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos.
Read MoreEmmaus Life Sciences, Inc., reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.
Read More